首页 › 基金 › FARALLON CAPITAL MANAGEMENT, L.L.C. › CRNX
FARALLON CAPITAL MANAGEMENT, L.L.C. 对 CRNX 的持仓历史
CRINETICS PHARMACEUTICALS IN
FARALLON CAPITAL MANAGEMENT, L.L.C. 在 Q2 2026 的 13F 申报中披露持有 CRNX(CRINETICS PHARMACEUTICALS IN)8,989,098 股,市值约 US$336.4M,约占其申报组合的 1.56%,在其申报持仓中市值排名第 22 位。 FARALLON CAPITAL MANAGEMENT, L.L.C. 最近 12 个申报季度中有 12 个季度披露了 CRNX 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
FARALLON CAPITAL MANAGEMENT, L.L.C. 对 CRNX 的持仓演变
FARALLON CAPITAL MANAGEMENT, L.L.C. 于 Q3 2023 首次披露 CRNX 持仓:361,904 股(约 US$10.8M)。 该持仓在 Q2 2026 达到峰值 8,989,098 股,市值约 US$336.4M。 在 12 次申报中,FARALLON CAPITAL MANAGEMENT, L.L.C. 9 次增持、2 次减持、0 次保持不变。 最近一期申报(Q2 2026)显示持股 8,989,098 股、市值约 US$336.4M,环比增持 651,000 股。。 持仓曾出现大幅变动:Q2 2024 增持约 9840%、Q3 2024 增持约 134%、Q4 2024 增持约 251%。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 361.90K | $10.76M | 新进 |
| Q4 2023 | 122.90K | $4.37M | 减持 |
| Q1 2024 | 5.00K | $234.05K | 减持 |
| Q2 2024 | 497.00K | $22.26M | 增持 |
| Q3 2024 | 1.16M | $59.38M | 增持 |
| Q4 2024 | 4.08M | $208.36M | 增持 |
| Q1 2025 | 4.61M | $154.45M | 增持 |
| Q2 2025 | 4.65M | $133.62M | 增持 |
| Q3 2025 | 5.77M | $240.32M | 增持 |
| Q4 2025 | 6.93M | $322.74M | 增持 |
| Q1 2026 | 8.34M | $302.84M | 增持 |
| Q2 2026 | 8.99M | $336.37M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 CRNX 与 13F 数据
CRNX(CRINETICS PHARMACEUTICALS IN)的行业分类暂缺。我们追踪的基金中还有 37 只申报持有 CRNX,申报仓位最大的包括:法拉龙资本管理 (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M), Bellevue Group AG (US$98.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 CRNX 的基金
- 法拉龙资本管理 8.99M 股 · $336.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.46M 股 · $241.87M · Q2 2026
- Bellevue Group AG 2.62M 股 · $98.04M · Q2 2026
- BAKER BROS. ADVISORS LP 2.35M 股 · $87.99M · Q2 2026
- Siren, L.L.C. 1.42M 股 · $53.17M · Q2 2026
- First Light Asset Management, LLC 1.36M 股 · $50.92M · Q2 2026
- Novo Holdings A/S 1.32M 股 · $49.39M · Q2 2026
- ADAR1 Capital Management, LLC 1.22M 股 · $45.73M · Q2 2026
- MONTANOVA CAPITAL, LLC 1.19M 股 · $44.39M · Q2 2026
- ORBIMED ADVISORS LLC 999.00K 股 · $37.38M · Q2 2026
更多关于 FARALLON CAPITAL MANAGEMENT, L.L.C.
常见问题
How long has FARALLON CAPITAL MANAGEMENT, L.L.C. held CRNX?
FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is FARALLON CAPITAL MANAGEMENT, L.L.C.'s current position in CRNX?
As of Q2 2026, FARALLON CAPITAL MANAGEMENT, L.L.C. holds 8.99M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $336.37M, representing 1.56% of its reported portfolio and ranking #22.
Has FARALLON CAPITAL MANAGEMENT, L.L.C. been buying or selling CRNX?
In the latest 13F filing (Q2 2026), FARALLON CAPITAL MANAGEMENT, L.L.C. increased its position in CRNX. The position peaked in Q2 2026 at 8.99M shares.
Which other funds hold CRNX?
Other major institutional holders of CRNX include 法拉龙资本管理, DRIEHAUS CAPITAL MANAGEMENT LLC, Bellevue Group AG, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.